There was a statistical trend (0.062) towards less use of betablocker therapy in the LBD group versus the AD group, and numerically greater use of angiotensin-converting enzyme inhibitors or angiotensin receptor blocker therapy. The gene discussed is ACE; the disease is Alzheimer disease.